Key Stats for GILD Stock
- Price Change for Gilead stock: 8%
- Current Share Price: $119
- 52-Week High: $121
- GILD Stock Price Target: $120
What Happened?
Gilead Sciences (GILD) stock surged more than 8% on Friday following a wave of analyst upgrades and price target increases after the biotech company raised its full-year guidance on strong HIV product performance.
Gilead increased its 2025 product sales guidance to $28.3 billion to $28.7 billion from its previous range of $28.2 billion to $28.6 billion, while boosting adjusted earnings per share expectations to $7.95 to $8.25 from $7.70 to $8.10.
The optimism centers around Gilead’s recently launched Yeztugo, a groundbreaking twice-yearly HIV prevention injection that received FDA approval in June.
For the second quarter, total revenue of $7.1 billion beat analyst estimates of $6.96 billion, driven by robust HIV sales growth of 7% to $5.1 billion.
Key HIV products showed strong momentum, with Biktarvy growing 9% to $3.5 billion and Descovy surging 35% to $653 million, its strongest quarter ever.
Adjusted earnings of $2.01 per share also exceeded expectations of $1.96, while the company’s base business (excluding COVID drug Veklury) grew 4% year-over-year to $6.9 billion.
See analysts’ growth forecasts and price targets for Gilead (It’s free!) >>>
What the Market Is Telling Us About GILD Stock
The bullish response to GILD stock reflects confidence in Gilead’s HIV franchise transformation, particularly around Yeztugo’s launch potential.
Truist upgraded GILD stock to ‘Buy’ from ‘Hold’ with a $127 price target, citing strong early demand indicators for Yeztugo and calling Gilead’s HIV business “best-in-class, unparalleled.”
Other firms followed with significant price target increases: Morgan Stanley to $143, BMO to $130, and Oppenheimer to $128.
CEO Daniel O’Day highlighted that Yeztugo represents “one of the most important scientific breakthroughs of our time” with transformative potential to “bend the arc of the HIV epidemic.”
Early launch metrics appear promising, with the first prescription written within hours of approval and high physician awareness levels at 72% unaided and 95% aided, well above typical launch benchmarks.
The strong performance comes despite ongoing challenges in Gilead’s cell therapy segment, though analysts remain optimistic about the pipeline, including Anitocel for multiple myeloma and Trodelvy’s expansion into first-line breast cancer treatment.
Despite the recent rally, GILD stock has returned just 45% to shareholders over the past decade.
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
